We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

An Observational Study For Ambrisentan (VOLT)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00679224
First Posted: May 16, 2008
Last Update Posted: March 23, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
GlaxoSmithKline
May 14, 2008
May 16, 2008
March 23, 2017
June 2008
July 2013   (Final data collection date for primary outcome measure)
safety monitoring
Not Provided
Complete list of historical versions of study NCT00679224 on ClinicalTrials.gov Archive Site
safety monitoring
Not Provided
Not Provided
Not Provided
 
An Observational Study For Ambrisentan
A Post-Marketing Observational Surveillance Programme for Ambrisentan (VOLT)
The purpose of the programme is to collect safety data on ambrisentan when used in clinical practice
The purpose of the programme is to collect safety data on ambrisentan when used in clinical practice
Observational
Observational Model: Other
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample
subjects who have been prescribed ambrisentan for a medically appropriate use. (See approved product label e.g. Summary of Product Characteristics. )
Hypertension, Pulmonary
Drug: ambrisentan
ambrisentan
ambrisentan prescribed subjects
ambrisentan prescribed subjects
Intervention: Drug: ambrisentan
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
800
July 2013
July 2013   (Final data collection date for primary outcome measure)
subjects who have been prescribed ambrisentan for a medically appropriate use (see approved product label)
Sexes Eligible for Study: All
Child, Adult, Senior
No
Contact information is only displayed when the study is recruiting subjects
Australia,   Belgium,   Canada,   Czech Republic,   Denmark,   France,   Germany,   Greece,   Italy,   Netherlands,   Norway,   Slovakia,   Spain,   Sweden,   United Kingdom
 
 
NCT00679224
110094
No
Not Provided
Not Provided
GlaxoSmithKline
GlaxoSmithKline
Not Provided
Study Director: GSK Clinical Trials GlaxoSmithKline
GlaxoSmithKline
March 2017